Overview

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Status:
Completed

Trial end date:
2017-10-04

Target enrollment:

Participant gender:

Summary

To assess the bioequivalence between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fasted state based on the pharmacokinetic (PK) evaluation of lesinurad and allopurinol in healthy adult subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Ardea Biosciences, Inc.

Treatments:

Allopurinol
Lesinurad